Advertisement
RESEARCH ARTICLE
Human umbilical cord matrix-derived stem cells exert trophic effects on β-cell survival in diabetic rats and isolated islets
Yunting Zhou, Qi Hu, Fuyi Chen, Juan Zhang, Jincheng Guo, Hongwu Wang, Jiang Gu, Lian Ma, Guyu Ho
Disease Models & Mechanisms 2015 8: 1625-1633; doi: 10.1242/dmm.021857

ABSTRACT

Human umbilical cord matrix-derived stem cells (uMSCs), owing to their cellular and procurement advantages compared with mesenchymal stem cells derived from other tissue sources, are in clinical trials to treat type 1 (T1D) and type 2 diabetes (T2D). However, the therapeutic basis remains to be fully understood. The immunomodulatory property of uMSCs could explain the use in treating T1D; however, the mere immune modulation might not be sufficient to support the use in T2D. We thus tested whether uMSCs could exert direct trophic effects on β-cells. Infusion of uMSCs into chemically induced diabetic rats prevented hyperglycemic progression with a parallel preservation of islet size and cellularity, demonstrating the protective effect of uMSCs on β-cells. Mechanistic analyses revealed that uMSCs engrafted long-term in the injured pancreas and the engraftment markedly activated the pancreatic PI3K pathway and its downstream anti-apoptotic machinery. The pro-survival pathway activation was associated with the expression and secretion of β-cell growth factors by uMSCs, among which insulin-like growth factor 1 (IGF1) was highly abundant. To establish the causal relationship between the uMSC-secreted factors and β-cell survival, isolated rat islets were co-cultured with uMSCs in the transwell system. Co-culturing improved the islet viability and insulin secretion. Furthermore, reduction of uMSC-secreted IGF1 via siRNA knockdown diminished the protective effects on islets in the co-culture. Thus, our data support a model whereby uMSCs exert trophic effects on islets by secreting β-cell growth factors such as IGF1. The study reveals a novel therapeutic role of uMSCs and suggests that multiple mechanisms are employed by uMSCs to treat diabetes.

INTRODUCTION

Diabetes is one of the most prevailing diseases worldwide. It is characterized by hyperglycemia resulting from an absolute or relative insulin deficiency. The chronic hyperglycemia of diabetes is associated with disabling damages of various organs such as the eye, kidneys, nerves and heart. The vast majority of cases of diabetes are type 1 diabetes (T1D) or type 2 diabetes (T2D), accounting for 5-10% and ∼90-95%, respectively (American Diabetes Association, 2014). All T1D and one-third of T2D are caused by substantial deficits in insulin-producing β-cells. Insulin administration is the principal treatment for these insulin-dependent diabetic patients. However, insulin given exogenously does not exactly mimic its physiological secretion and carries the risk of the patient developing hypoglycemia or secondary diabetic complications. Replenishment of deficient β-cells through islet transplantation offers ideal therapeutic outcomes, yet the option is limited by the donor availability, graft survival and complications associated with the long-term use of immunosuppressants (Bromberg et al., 2007; Gruessner and Gruessner, 2013). Exploiting the regenerative capacity of stem cells has thus emerged as a novel approach to complement the current therapies.

Adult mesenchymal stem cells (MSCs), owing to their multipotent and modulatory properties, are intensely used in regenerative medicine (Volarevic et al., 2011). MSCs were first isolated from the bone marrow and have since been found in almost all postnatal tissues. Bone-marrow-derived MSCs (bMSCs) remain as the gold standard in clinical applications. However, bMSCs have specific problems that limit their use. For instance, bMSCs are present at a low frequency in the marrow compartment; the cell-harvesting procedure is painful and invasive; and bMSCs exhibit a reduced ex vivo expansion capacity as the donor age increases (Batsali et al., 2013; Watson et al., 2015). On the other hand, human uMSCs can be obtained in large quantities; the cell harvesting is non-invasive; uMSCs are primitive and highly expandable (Troyer and Weiss, 2008); and they can undergo freeze-and-thaw for convenient off-the-shelf use. Studies have also shown that uMSCs do not spontaneously transform in culture (Tang et al., 2013) or form teratomas upon transplantation (Troyer and Weiss, 2008). These cellular features and procurement advantages make uMSCs a promising cell source in cell-based therapies.

Human uMSCs are currently under clinical investigations to treat diabetes (Berezin, 2014). Although the preliminary data from both T1D and T2D studies are promising (Hu et al., 2013; Kong et al., 2014), the mode of action remains to be understood. Because there is little evidence to indicate that MSCs are capable of differentiating into insulin-producing cells in vivo (Hess et al., 2003; Lechner et al., 2004; Lee et al., 2006; Taneera et al., 2006), the contribution of differentiation to the treatment effect is likely minimal. MSCs possess the immunomodulatory activity (Abdi et al., 2008; Nauta and Fibbe, 2007), which is shown to be associated with ameliorating hyperglycemia in autoimmune diabetic mice (Bassi et al., 2012; Ezquer et al., 2012). The immunomodulatory function of MSCs could explain the therapeutic benefits seen in T1D, which is caused by immune-mediated β-cell destruction. Yet the mere immune modulation might not be adequate to explain the efficacy seen in T2D, where the β-cell death is chiefly caused by glucotoxicity (Bensellam et al., 2012). It seems that additional mechanisms underlie the therapeutic effect of uMSCs in the treatment of diabetes.

TRANSLATIONAL IMPACT

Clinical issue

Diabetes is one of the most prevailing diseases worldwide. All cases of type I and one-third of cases of type 2 diabetes are caused by deficits in insulin-producing β-cells. The standard of care for these patients is insulin injection. Yet the treatment has many drawbacks. For instance, patients can experience life-threatening hypoglycemia and many develop disabling diabetic complications. Stem cells, owing to their capacity to differentiate into replacement cells and repair damaged tissues, have emerged as innovative therapies to complement current treatment options. Mesenchymal stem cells from the human umbilical cord matrix (uMSCs) have already shown clinical promise for the treatment of diabetes. However, given that there is little evidence that uMSCs can differentiate into insulin-producing cells in vivo, the mechanisms that underlie this promise are not fully understood.

Results

Here, the authors use a chemical agent that specifically destroys β-cells to generate diabetic rats and show that infusion of uMSCs into these diabetic rats prevents hyperglycemia by improving insulin secretion and increasing islet cell numbers (85% of islet cells are β-cells). Then, using in vivo cell tracking, morphological and biochemical techniques, they show that uMSCs engraft in the chemically injured pancreas and secrete abundant β-cell growth factors, including IGF1. They subsequently show that uMSC engraftment activates the PI3K signaling pathway, which suggests that growth factors secreted by the uMSCs might be the mediators between the protective effect of uMSCs and β-cell survival. To support this assumption, they show that uMSCs promote islet cell survival and insulin secretion in an in vitro islet and uMSC co-culture model, and that reduction of IGF1 secretion from uMSCs using RNA interference diminishes the protective effects of uMSCs on islets.

Implications and future directions

Human uMSCs are hypoimmunogenic – they either lack, or express low levels of, cell surface molecules capable of stimulating an immune response. In addition, uMSCs suppress lymphocyte activation and induce immune tolerance. These immunosuppressive properties of uMSCs are thought to underlie the therapeutic basis of uMSCs in the treatment of diabetes. The current findings demonstrate, however, that uMSCs can also exert direct protection against β-cell death by secreting β-cell growth factors such as IGF1. Thus, this study identifies a new therapeutic role for uMSCs and suggests that uMSCs might operate through multiple mechanisms to treat diabetes.

MSCs secret a broad spectrum of growth factors and extracellular matrix (ECM) molecules that are increasingly thought to be central to the tissue repair (Baraniak and McDevitt, 2010). These biomolecules can act in a paracrine fashion to promote angiogenesis and ECM remodeling (Baraniak and McDevitt, 2010). Neovascularization has been observed in the damaged pancreas after bMSC transplantation (Ito et al., 2010; Rosengren et al., 2009). Here, we tested whether uMSCs exerted direct trophic effects on β-cells by using the chemically induced diabetes model as well as the ex vivo islet and uMSC co-culture system.

RESULTS

Systemic administration of uMSCs prevents hyperglycemic progression and body weight loss of STZ-induced diabetic rats

The diabetic rat model was established by a single-dose injection of streptozotocin (STZ), which specifically destroys β-cells (Lenzen, 2008). The STZ administration resulted in a rise in blood glucose from euglycemic 6.06 mmol/l to 24.24 mmol/l in 7 days, representing a fourfold increase. Human uMSCs were then systemically administered (day 0). The blood glucose of untransplanted rats continued to rise, reaching 30.60 mmol/l at day 18, but stabilized thereafter (Fig. 1A). The uMSC transplantation retarded hyperglycemic progression at day 6, with the blood glucose becoming modestly lower thereafter (Fig. 1A). The cell treatment also prevented the body weight loss (Fig. 1B). The findings support our previous observation that uMSCs offer therapeutic benefits to diabetic rats (Wang et al., 2014).

Fig. 1.
Fig. 1.

Effects of uMSC transplantation on hyperglycemia and body weight of STZ-induced diabetic rats. STZ-treated rats with overt hyperglycemia were injected with either uMSCs or vehicle and the blood glucose level (A) and body weight (B) were measured every 3 days for 42 days. Asterisks (*) denote statistical differences (P<0.05) between the uMSC-transplanted and untransplanted rats (n=8/group).

The rat-specific insulin and C-peptide in the serum were measured at day 42 after transplantation. Both parameters were doubled in value after the cell treatment but neither was fully restored, with insulin at 53% and C-peptide at 79% of normal controls (Fig. 2A). Histological analysis showed that untransplanted rats had a markedly reduced islet size and cell number (Fig. 2B); uMSC transplantation partially restored the morphology, with the islet size at 63% and cell number at 42% of normal controls (Fig. 2C). Immunohistochemical analysis further supported the improved islet mass and insulin secretion in transplanted rats (Fig. 2B). Consistent with our previous report (Wang et al., 2014), expression of the human insulin gene was undetectable in the transplanted rat pancreas (data not shown). The data demonstrate that the therapeutic benefits conferred by uSMC transplantation resulted from the preservation/restoration of islet morphology and function.

Fig. 2.
Fig. 2.

Effects of uMSC transplantation on islet function and morphology of STZ-induced diabetic rats. uMSC-transplanted and untransplanted rats were euthanized at 42 days. The rat insulin and C-peptide levels in the serum were measured using the rat-specific ELISA (A). The islet morphology was examined by HE staining and insulin content in the islet was examined by insulin immunohistochemistry; the representative photomicrographs are shown and islets are indicated by black arrows (B). The islet area and cellularity were quantified as described in the Materials and Methods (C). Magnification was at the 40× objective field. *P<0.05; **P<0.01; ***P<0.001. n=8/group.

Human uMSCs home to the injured pancreas and express genes and proteins of β-cell growth factors

One of the MSC characteristics is the ability to preferentially home to injured tissues upon systemic administration (Deak et al., 2010). To ascertain the pancreatic localization of uMSCs in the diabetic rats, uMSCs were labeled with the fluorescent dye CM-Dil. Studies have shown that CM-Dil does not affect cell viability, proliferation or differentiation (Weir et al., 2008). The in vitro cell labeling efficiency was >90% and labeled uMSCs were administered to the diabetic rats. The pancreas as well as the lung and liver, which are rich in blood supply, were examined at 21 and 42 days after the cell infusion. The CM-Dil fluorescence was found clustering around damaged islets at both time points (Fig. 3A). In contrast, little or no fluorescence was found in the lung or liver (Fig. 3A). Infusion of labeled uMSCs ameliorated hyperglycemia and body weight loss of diabetic rats to a similar degree as with unlabeled uMSCs (data not shown), confirming that the labeling did not affect uMSC function.

Fig. 3.
Fig. 3.

uMSCs engraft and express genes and proteins of β-cell growth factors in diabetic rats. (A) Rats transplanted with CM-Dil-labeled uMSCs were euthanized at 21 and 42 days. Sections of the pancreas, lung and liver were examined for CM-Dil fluorescence (red) and the cell population in the section was examined by DAPI staining (blue). Representative photomicrographs with the 40× objective field are shown. (B) Pancreatic mRNA levels of the indicated human genes from transplanted and untransplanted rats (n=6/group) were assessed at 21 and 42 days by qPCR using the human-specific primers with GAPDH as internal controls. (C) The corresponding human proteins in the serum of rats (n=6/group) were assessed using the human-specific ELISA kits. *P<0.05 was compared with the 21-day transplanted group.

Because of the pancreatic localization of uMSCs, the pancreas of transplanted rats was screened for expression of human-specific genes of insulin-like growth factor 1 (IGF1), hepatocyte growth factor (HGF) and platelet-derived growth factor alpha (PDGFA) by qPCR. These growth factors, with the cognate receptors expressed on β-cells, have been shown to stimulate β-cell expansion and protect against STZ-induced β-cell death in mice (Chen et al., 2011; Dai et al., 2005; Garcia-Ocana et al., 2000; George et al., 2002). In addition, we examined the expression of tissue inhibitor of metalloproteinase 1 (TIMP1), which promotes β-cell survival under inflammatory conditions and is highly produced by human adipose-derived MSCs (aMSCs) (Kono et al., 2014). The mRNAs of human IGF1, HGF and PDGFA were detected at both 21 and 42 days after the cell transplantation, with the IGF1 mRNA level being the highest (Fig. 3B). Assessment of the protein secretion in the serum using the human-specific ELISA showed substantial levels at both time points, with the serum levels of human IGF1, HGF and PDGFA at 704, 142 and 55 pg/ml, respectively, at day 42 (Fig. 3C). These factors showed little change at either the mRNA or protein levels between the two time points (Fig. 3B,C). The assay specificities were confirmed by undetectable levels of corresponding human mRNAs or proteins in the untransplanted rat (Fig. 3B,C). Neither the mRNA nor protein of human TIMP1 was detected in transplanted rats (Fig. 3B,C).

Human uMSCs activate the PI3K pathway in the injured pancreas

IGF1, HGF and PDGFA are shown to activate the PI3K and ERK1/2 pathways in isolated islets or β-cell lines (Chen et al., 2011, 2014; Dai et al., 2005). The abundant production of the growth factors by uMSCs prompted us to assess the activation state of the two signaling pathways in the pancreas. Shown in Fig. 4A, a marked Akt, but not ERK1/2, phosphorylation was seen in the transplanted pancreas. To rule out the contribution of human pAkt owing to the uMSC engraftment, we assessed the relative mRNA levels between the rat and human GAPDHs in the pancreas. The ratio, as evaluated by qPCR, was >1000. Thus, the human pAkt, if any, was negligible in the pAkt level observed. Assessment of the downstream anti- and pro-apoptotic effectors of Bcl-2 and caspase-3 showed a 2.1-fold elevation and 52% reduction, respectively, in transplanted compared with untransplanted rats (Fig. 4A). The data demonstrate that uMSC transplantation activated the pancreatic PI3K pathway with subsequent activation of the anti-apoptotic machinery. Because of high systemic levels of the growth factors, especially uMSC-secreted IGF1, we evaluated the impact on pAkt and pERK1/2 levels in the liver. In contrast to the pancreas, the liver pAkt exhibited a modest reduction in transplanted rats as compared with the untransplanted control (Fig. 4B). The liver pERK1/2 level did not differ between the two groups (Fig. 4B).

Fig. 4.
Fig. 4.

Assessment of pathway activation in the pancreas and liver of uMSC-transplanted rats. Pancreatic or liver tissues from the uMSC-transplanted and untransplanted rats (n=6/group) were collected at 42 days. (A) Levels of pAkt, pERK1/2, Bcl-2 and caspse-3 in the pancreas were analyzed by western blots and quantification was normalized against β-actin. (B) The liver pAkt and pERK1/2 were assessed as in A. *P<0.05 and ***P<0.001 were compared with the STZ group.

Human uMSCs improve the viability and function of rat islets in co-culture

To support the direct trophic effect of uMSCs on islets (containing 85% β-cells) and that the secreted factors mediated the effect, uMSCs were co-cultured with isolated rat islets in transwell plates, in which only soluble factors were freely passable between the two cell compartments. The islet culture alone exhibited a progressive cell death; the cell viability at day 6 was 37% of that of day 1 but was improved by 42% of this day-6 value in the co-culture (Fig. 5A). Similarly, the islet culture alone exhibited a progressive decline in insulin secretion; the insulin level at day 6 was 57% of that of day 1 and was enhanced by 21% in the co-culture (Fig. 5B). The data demonstrate that uMSCs exerted direct pro-survival effects on islets.

Fig. 5.
Fig. 5.

Assessment of the rat islet survival/function and uMSC-secreted growth factors in culture. Freshly isolated rat islets were cultured alone or with uMSCs for the indicated time points. The islet cell viability was measured using the MTS assay (A) and the rat insulin level in supernatants was measured using the rat-specific ELISA (B). Supernatants from the uMSC or islet-alone culture or the co-culture were taken at the indicated times, and levels of human IGF1, HGF and PDGFA were measured using the human-specific ELISA kits (C). The data are representatives of at least three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 indicate the statistical significance between the uMSC and islet/uMSC cultures.

To assess the secretion of IGF1, HGF and PDGFA by uMSCs in culture, uMSCs were cultured alone or co-cultured with islets and the supernatants were taken for the measurement using the human-specific ELISA. As shown in Fig. 5C, these factors were produced with the same rank order as that observed in vivo, with IGF1 being the highest. Notably, their productions were augmented by co-culturing with islets. The IGF1 level in the co-culture at day 6 was 43 ng/ml, which was sevenfold higher than HGF and 24-fold higher than PDGFA (Fig. 5C). The assay specificity was again confirmed by undetectable levels of the human proteins in the rat islet culture alone (Fig. 5C). The TIMP1 production by uMSCs in culture was also undetectable (data not shown).

The uMSC-secreted IGF1 promotes the islet cell survival and function

Because of the abundant production of human IGF1 both in vivo and in vitro, we investigated the contribution of uMSC-secreted IGF1 to islet viability and function by using siRNA knockdown. Our preliminary studies showed that transfection of the IGF1-specific siRNA to uMSCs gave the best protein knockdown at 48 h (data not shown). Thus, uMSCs transfected for 48 h with either the specific or scrambled siRNA were utilized in the co-culture studies. As shown in Fig. 6A, the IGF1 production was persistently reduced by the IGF1 siRNA in the 6-day co-culture. The area under the curve of the IGF1 production in the 6-day specific knockdown co-culture was reduced by 27% as compared with the scrambled control (Fig. 6B). In parallel assays, the islet viability was diminished in both 3-day and 6-day co-cultures, with a 17% reduction in the 6-day co-culture (Fig. 6C); the insulin secretion was reduced by 14% in the 6-day co-culture (Fig. 6D). Thus, the data establish the crucial contribution of uMSC-secreted IGF1 to islet survival and function.

Fig. 6.
Fig. 6.

Effects of reduced IGF1 secretion by uMSCs on islet survival and function in co-culture. uMSCs transfected with either the IGF1-specific or scrambled siRNA were co-cultured with islets for up to 6 days. The human IGF1 levels in supernatants were measured at the indicated time points (A) and the area under the curve of the human IGF1 production in the 6-day culture was calculated (B). In parallel experiments, the islet survival (C) and insulin secretion (D) were measured. The data are representatives of at least three independent experiments. *P<0.05 and ***P<0.001 indicate the statistical significance between the scrambled and IGF1 siRNA cultures.

DISCUSSION

In this study, the diabetic model was generated by a single large-dose injection of STZ. Under such conditions, STZ destroys β-cells via DNA alkylation (Lenzen, 2008). The model differs from the autoimmune diabetic model of non-obese diabetes (NOD) or multiple low-dose STZ-induced diabetes, where islet inflammation is the salient pathological feature (Bassi et al., 2012; Ezquer et al., 2012; George et al., 2002; Leiter, 1982; Paik et al., 1980). The non-inflammatory diabetic model used here, which was confirmed by the lack of inflammatory cell infiltrates in the islet of untransplanted but STZ-treated rats (Fig. 2B), allows us to better examine the direct trophic effect of uMSCs on β-cell survival with fewer complications from their immunomodulatory activities. In this study, uSMC transplantation retarded the hyperglycemic progression 6 days after the treatment, yet the treatment only modestly reversed hyperglycemia despite the extended 42-day treatment. Multiple factors might influence the efficacies. Because the transplanted cells were apparently alive and functional for the entire 42 days (discussed below), we suspect that the delayed treatment intervention (i.e. the glucose level was already fourfold higher than normal) limited the efficacy. An earlier intervention with more residual islets left for regeneration might produce better therapeutic outcomes.

Human uMSCs were found localized to the injured pancreas but not the lung or liver. The finding concurs with the general homing characteristics of MSCs to injured tissues (Deak et al., 2010) and the homing pattern of human bMSCs in diabetic mice (Lee et al., 2006). Notably, the xenogeneic graft survived long-term in the absence of immunosuppressants. The successful engraftment was further supported by the stable expression of human genes in the rat pancreas. Because of the lack of inflammatory infiltrates in and around the islet of transplanted rats (Fig. 2), uMSCs did not seem to have provoked the host immune response. Our data support the long-held notion that uMSCs are hypoimmunogenic (Weiss et al., 2008, 2006), which, coupled with the immunosuppressive property (McGuirk and Weiss, 2011), might have contributed to the muted graft rejection. Studies have reported that transplantation of human uMSCs in immunocompetent rats results in functional improvements of damaged organs (Lopez et al., 2013; Weiss et al., 2006); however, the cell fate in vivo is not clear. The demonstration that uMSCs can survive long-term and remain functional in xenogeneic hosts could have clinical implications. For instance, it might help project the cell treatment frequency and suggest a reduced or even eliminated immunosuppressant use in the allogeneic cell therapies.

Consistent with the stable mRNA expression in the pancreas, human IGF1, HGF and PDGFA proteins were stably detected in the serum of transplanted rats, among which IGF1 was most abundant. The local concentrations in the pancreas, where the proteins were produced, could be even higher and might thus act effectively as the β-cell trophic factors. In support, a marked activation of the pancreatic PI3K pathway and downstream anti-apoptotic machinery was evident. We also analyzed the pro-growth potential of the PI3K activation by assessing the downstream cell-cycle genes such as cyclin D1, cyclin D2, p21 and p27. Expression of these genes is involved in β-cell proliferation (Heit et al., 2006). We saw ∼twofold upregulation of the cyclin D2 mRNA level but expression of the other genes was unchanged in the pancreas of transplanted rats (data not shown). The limited expression changes of cell-cycle genes imply that the β-cell expansion was restrained, which agrees with the modest reversal of hyperglycemia observed. These biochemical data suggest that the anti-apoptotic activity of uMSCs is the main contributor to the improved islet size found in the histological study. Despite the marked activation of the pancreatic PI3K pathway, we did not see pancreatic ERK1/2 activation. We suspect that, in contrast to the fundamental role of PI3K in β-cell survival (Bernal-Mizrachi et al., 2001; Tuttle et al., 2001), the role of ERK might be auxiliary and that a modest activation in β-cells could be masked by the whole-tissue extracts used in the analysis.

The siRNA knockdown experiment showed that a 27% reduction in uMSC-secreted IGF1 led to a 17% reduction of β-cell survival. Although the study illustrates the major role of uMSC-secreted IGF1, the disproportionate reduction implies that other β-cell trophic factors, although playing minor roles, are required to fully support the β-cell survival. The uMSC-secreted HGF and PDGFA, both produced in the nM range in co-cultures and detectable in transplanted rats, could be the other possible mediators. It is worthy of noting that secretion of these factors by uMSCs was induced by islet cells. An augmentation of aMSC-secreted factors by islet cells has also been observed (Kono et al., 2014). Although the molecular mechanism underlying the cross-talk between uMSCs and islets remains to be elucidated, the induced production by islets, in conjunction with the long-term survival of uMSCs in the injured pancreas, could argue in favor of cell-based over factor-based strategies in diabetes treatment (Baraniak and McDevitt, 2010).

The β-cell growth factors secreted by uMSCs are pleotrophic (Clemmons and Maile, 2003; Nakamura et al., 2011; Ronnstrand, 2004). Whether their systemic exposure leads to undesired effects should be of clinical concern. Transplantation of uMSCs reduced the pAkt level and had no effect on pERK1/2 in the liver of transplanted rats, which might suggest a low potential in the proliferative growth of normal tissues. IGF1 is noted to act mainly on injured tissues (Agudo et al., 2008). Nevertheless, the liability should be assessed over a longer term. We should also point out that these growth factors might play multiple roles in pancreas repair. For instance, PDGFA is also a potent angiogenic factor (Shibuya, 2013) and angiogenesis could be important for islet regeneration (Ito et al., 2010; Rosengren et al., 2009). IGF1 has recently being shown to stimulate regulatory T (Treg) cells and suppress autoimmune diabetes in mice (Anguela et al., 2013; Bilbao et al., 2014). In the study, the recombinant human IGF1 delivered by minipumps to maintain a serum level of ∼350 pg/ml is efficacious in the treatment of diabetes (Bilbao et al., 2014). Using this dose as a gauge, IGF1 stably produced by uMSCs with the serum level of 704 pg/ml and possibly higher levels in the pancreas might exert dual trophic and immunomodulatory functions to preserve/regenerate islets. Notably, IGF1 might also contribute to the efficacy by enhancing insulin sensitivity in diabetic individuals (Clemmons, 2012).

In conclusion, we have two key novel findings in this study: (1) uMSCs exert trophic effects on β-cell survival by activating the pancreatic PI3K pathway; and (2) the trophic effect is mediated by uMSC-secreted factors, among which IGF1 might play a major role.

MATERIALS AND METHODS

Animals

Sprague Dawley (SD) rats were purchased from the Animal Center of Shantou University Medical College. Animals were housed under standard conditions with food and water given ad libitum. All experimental procedures were conducted in accordance with the guidelines published in the Ministry of Science and Technology of China for the Care and Use of Laboratory Animals and approved by the Animal Care and Welfare Committee of Shantou University Medical College.

Isolation and expansion of uMSCs

Protocols for obtaining human umbilical cords were reviewed and approved by the Medical Ethics Committee of Shantou University Medical College (SUMC2013XM-0036). The umbilical cord donors gave informed consent. Isolation of uMSCs was carried out as described (Tang et al., 2013). Isolated uMSCs were cultured at 37°C with 5% CO2 in growth medium containing GlutaMAX™-1, 10% FBS and 1% penicillin-streptomycin (all from Gibco, USA). The cells were expanded for 2-4 passages before use.

Induction of diabetes and cell transplantation

Eight-week-old SD rats were given the intraperitoneal injection of STZ at 65 mg/kg body weight (Sigma, USA) dissolved in 0.01 M citrate buffer at pH 4.2 or the buffer alone. Blood glucose was measured daily with the Glucotrend glucose meter (Roche Diagnostics, Switzerland) for the first 7 days to confirm the establishment of diabetic conditions. At day 7 after the STZ treatment, rats were administered, via the tail vein, either 3×106 uMSCs in 200 μl PBS or the vehicle. Blood glucose and body weight were measured every 3 days thereafter for 42 days.

Tissue collection

Rats were euthanized using 10% chloral hydrate at 0.4 ml/100 g body weight at 21 or 42 days after the cell injection. The trunk blood was collected and the serum was obtained and stored at −80°C until use. The pancreas and liver from each rat were quickly removed. A main portion of the pancreas was fixed with 4% paraformaldehyde and embedded in paraffin for histological and immunohistochemical analyses. The remaining pancreas and liver were immediately snap-frozen in liquid nitrogen and stored at −80°C for PCR and western blot analyses.

In vivo cell tracking

Human uMSCs were labeled with CM-Dil according to the manufacturer's instructions (Invitrogen, USA). The labeling efficiency was examined under fluorescent microscopy and the viability of labeled cells was confirmed by their ability to grow in vitro. After labeling, cells were washed with PBS and 3×106 cells were injected into the STZ-treated rats as above. Rats were euthanized at the indicated times and paraffin sections (4-µm thickness) of selected tissues were stained with DAPI (Vectashield, USA) for 5 min at room temperature. The CM-Dil and DAPI staining was visualized and acquired by the fluorescent microscopy (Olympus f1000, Japan).

Immunohistochemistry

Paraffin sections (4-µm thickness) were stained with hematoxylin and eosin (HE) for histological examination. For the immunohistochemical detection of insulin, paraffin sections were incubated with the rabbit anti-rat insulin antibody (cat#4590, Cell Signaling Technology, USA) at 1:100 dilution, followed by incubation with the HRP-conjugated anti-rabbit secondary antibody (cat#PV-9000, ZSGB-BIO, China) and development with the HRP-AEC kit (GENMED Scientifics, USA). Sections were then counterstained with hematoxylin and examined under the light microscope (Leica DM2000, Germany). For measurement of the islet area, islets in HE sections were identified and the islet area was measured using Image-Pro software (Media Cybernetics, USA). The average islet area from each rat was determined from 4-5 sections spaced >200 μm apart. The cell number per islet area in the same section was counted using Image-Pro (Media Cybernetics, USA) and the average cell number per islet from each rat was determined in the same manner as that of the islet area.

Quantitative PCR

Total RNAs of the pancreas were extracted using TRIzol according to the manufacturer's instructions (Life Technologies, USA). Total RNAs (1 μg) were reverse-transcribed using the Transcriptor First-strand cDNA Synthesis kit (Takara, Japan) and qPCR was performed using the SYBR® Premix Ex Taq™ II kit (Takara, Japan). Human-specific primers for the indicated genes were designed using the GenBank database and are listed in Table 1. Reactions were run in the 7500 Fast Real-Time PCR System (Applied Biosystems, USA) under the following conditions: 95°C for 15 min, followed by 40 cycles of 94°C for 15 s, 55°C for 30 s and 72°C for 30 s. Quantification of relative mRNA levels was performed using the ΔCt method (Livak and Schmittgen, 2001) with the 7500 Software v2.0.6 (Applied Biosystems, USA).

View this table:
Table 1.

The human primer sequences used in qPCR

Western blot analysis

Proteins were extracted from tissues using the RIPA buffer (Cell Signaling Technology, USA) containing 1 mM NaF and 1 mM phenylmethylsulfonyl fluoride (PMSF; Solarbio, China). Protein concentrations were determined using the BCA assay (Thermo Scientific, USA). Equivalent amounts of protein samples were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. The primary antibodies used were rabbit anti-phospho-Akt (cat#4060s), rabbit anti-phospho-ERK1/2 (cat#4370s), rabbit anti-caspase-3 (cat#9664) and rabbit anti-Bcl-2 (cat#2870) (all from Cell Signaling Technology, USA; used at 1:1000 dilution) or the mouse anti-β-actin (TA09, ZS-Bio, China; used at 1:2000). The secondary antibodies used were IRDye 680RD-conjugated goat anti-rabbit (cat#926-32220) or IRDye 800CW-conjugated goat anti-mouse (cat#926-32211) antibodies (LI-COR, USA; used at 1:10,000). The band density was scanned using the Odyssey Two-Color Infrared Imaging System (LI-COR, USA) and quantified using the Quantity One System (Bio-Rad, USA).

Rat islet isolation and co-culture

Rat islets were isolated and purified as described previously (Peng et al., 2009). A total of 70-100 rat islets were used per well. For co-culture experiments, 1×105 uMSCs were seeded into the lower chamber of the 24-well transwell plate (Corning, USA) containing the co-culture medium (i.e. the growth medium with only 5% FBS). Immediately after uMSCs became attached, the medium was changed and freshly isolated islets were placed into the upper chamber. The plates were incubated at 37°C with 5% CO2 for the indicated times before the analysis.

siRNA knockdown

Human uMSCs were seeded into the lower chamber of the 24-well transwell plate and grown to 70-80% confluence. The human-specific IGF1 siRNA (5′-ACCUUGUCUAAGUGGUUUA-3′) or scrambled siRNA (Gene Pharma, China) was transfected using the Lipofectamine RNAiMAX Reagent according to the manufacturer's instructions (Invitrogen, USA). Transfected uMSCs were cultured in the growth medium for 48 h before the medium was replaced with the co-culture medium. Freshly isolated islets were then placed in the upper chamber for co-culture studies.

Cell viability and ELISA

Cell viability was measured by the colorimetric MTS assay (absorbance at 490 nm) according to the manufacturer's instructions (Promega, USA). Rat insulin and C-peptide in sera and culture supernatants were measured using the ultrasensitive rat-specific ELISA kit as specified (MeilianBio, China). The 24-h basal insulin secretion in rat islet cultures was assessed as follows: the medium was changed on the day specified and the rat insulin level in the supernatant was measured 24 h later. The levels of human IGF1, HGF and PDGFA in the serum and supernatants were quantified using the human-specific ELISA kits according to the manufacturer's instructions (Abcam, USA).

Statistical analysis

The Student's t-test and one-way ANOVA were used for group comparisons (GraphPad Software Inc., USA). Data were expressed as the mean±standard error of the mean (s.e.m.). P<0.05 was considered statistically significant.

Acknowledgements

We thank Professor Chi-ju Wei at Shantou University for his valuable guidance for rat islet isolation.

Footnotes

  • Competing interests

    The authors declare no competing or financial interests.

  • Author contributions

    Y.Z. and Q.H. designed and performed the experiments, analyzed data, and prepared the manuscript. F.C. and J.Z. contributed to cell culture, tissue collection and data analysis. J.Guo contributed to the siRNA knockdown. L.M., J.Gu and H.W. contributed to the data analysis. G.H. conceived, designed and directed the study, and wrote the manuscript.

  • Funding

    This work was supported by grants (52102-710020 and 2015A030313445) from the Overseas Recruitment Fund for Universities and the Natural Science Foundation in Guangdong, China (to G.H.).

  • Received June 10, 2015.
  • Accepted September 11, 2015.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Abdi, R.,
    2. Fiorina, P.,
    3. Adra, C. N.,
    4. Atkinson, M. and
    5. Sayegh, M. H.
    (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57, 1759-1767. doi:10.2337/db08-0180
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Agudo, J.,
    2. Ayuso, E.,
    3. Jimenez, V.,
    4. Salavert, A.,
    5. Casellas, A.,
    6. Tafuro, S.,
    7. Haurigot, V.,
    8. Ruberte, J.,
    9. Segovia, J. C.,
    10. Bueren, J. et al.
    (2008). IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 51, 1862-1872. doi:10.1007/s00125-008-1087-8
    OpenUrlCrossRefPubMed
  3. ↵
    American Diabetes Association (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care 37 Suppl. 1, S81-S90. doi:10.2337/dc14-S081
    OpenUrlFREE Full Text
  4. ↵
    1. Anguela, X. M.,
    2. Tafuro, S.,
    3. Roca, C.,
    4. Callejas, D.,
    5. Agudo, J.,
    6. Obach, M.,
    7. Ribera, A.,
    8. Ruzo, A.,
    9. Mann, C. J.,
    10. Casellas, A. et al.
    (2013). Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. Diabetes 62, 551-560. doi:10.2337/db11-1776
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Baraniak, P. R. and
    2. McDevitt, T. C.
    (2010). Stem cell paracrine actions and tissue regeneration. Regen. Med. 5, 121-143. doi:10.2217/rme.09.74
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bassi, E. J.,
    2. Moraes-Vieira, P. M. M.,
    3. Moreira-Sa, C. S. R.,
    4. Almeida, D. C.,
    5. Vieira, L. M.,
    6. Cunha, C. S.,
    7. Hiyane, M. I.,
    8. Basso, A. S.,
    9. Pacheco-Silva, A. and
    10. Camara, N. O. S.
    (2012). Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 61, 2534-2545. doi:10.2337/db11-0844
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Batsali, A. K.,
    2. Kastrinaki, M.-C.,
    3. Papadaki, H. A. and
    4. Pontikoglou, C.
    (2013). Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr. Stem Cell Res. Ther. 8, 144-155. doi:10.2174/1574888X11308020005
    OpenUrlCrossRefPubMed
  8. ↵
    1. Bensellam, M.,
    2. Laybutt, D. R. and
    3. Jonas, J.-C.
    (2012). The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol. Cell. Endocrinol. 364, 1-27. doi:10.1016/j.mce.2012.08.003
    OpenUrlCrossRefPubMed
  9. ↵
    1. Berezin, A. E.
    (2014). Diabetes mellitus and cellular replacement therapy: expected clinical potential and perspectives. World J. Diabetes 5, 777-786. doi:10.4239/wjd.v5.i6.777
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bernal-Mizrachi, E.,
    2. Wen, W.,
    3. Stahlhut, S.,
    4. Welling, C. M. and
    5. Permutt, M. A.
    (2001). Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J. Clin. Invest. 108, 1631-1638. doi:10.1172/JCI200113785
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Bilbao, D.,
    2. Luciani, L.,
    3. Johannesson, B.,
    4. Piszczek, A. and
    5. Rosenthal, N.
    (2014). Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Mol. Med. 6, 1423-1435. doi:10.15252/emmm.201303376
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Bromberg, J. S.,
    2. Kaplan, B.,
    3. Halloran, P. F. and
    4. Robertson, R. P.
    (2007). The islet transplant experiment: time for a reassessment. Am. J. Transplant. 7, 2217-2218. doi:10.1111/j.1600-6143.2007.01957.x
    OpenUrlCrossRefPubMed
  13. ↵
    1. Chen, H.,
    2. Gu, X.,
    3. Liu, Y.,
    4. Wang, J.,
    5. Wirt, S. E.,
    6. Bottino, R.,
    7. Schorle, H.,
    8. Sage, J. and
    9. Kim, S. K.
    (2011). PDGF signalling controls age-dependent proliferation in pancreatic beta-cells. Nature 478, 349-355. doi:10.1038/nature10502
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Chen, Z.,
    2. Morris, D. L.,
    3. Jiang, L.,
    4. Liu, Y. and
    5. Rui, L.
    (2014). SH2B1 in beta-cells promotes insulin expression and glucose metabolism in mice. Mol. Endocrinol. 28, 696-705. doi:10.1210/me.2013-1333
    OpenUrlCrossRefPubMed
  15. ↵
    1. Clemmons, D. R.
    (2012). Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol. Metab. Clin. North Am. 41, 425-443, vii-viii. doi:10.1016/j.ecl.2012.04.017
    OpenUrlCrossRefPubMed
  16. ↵
    1. Clemmons, D. R. and
    2. Maile, L. A.
    (2003). Minireview: integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 144, 1664-1670. doi:10.1210/en.2002-221102
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Dai, C.,
    2. Huh, C.-G.,
    3. Thorgeirsson, S. S. and
    4. Liu, Y.
    (2005). Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am. J. Pathol. 167, 429-436. doi:10.1016/S0002-9440(10)62987-2
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Deak, E.,
    2. Seifried, E. and
    3. Henschler, R.
    (2010). Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int. Rev. Immunol. 29, 514-529. doi:10.3109/08830185.2010.498931
    OpenUrlCrossRefPubMed
  19. ↵
    1. Ezquer, F.,
    2. Ezquer, M.,
    3. Contador, D.,
    4. Ricca, M.,
    5. Simon, V. and
    6. Conget, P.
    (2012). The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells 30, 1664-1674. doi:10.1002/stem.1132
    OpenUrlCrossRefPubMed
  20. ↵
    1. Garcia-Ocana, A.,
    2. Takane, K. K.,
    3. Syed, M. A.,
    4. Philbrick, W. M.,
    5. Vasavada, R. C. and
    6. Stewart, A. F.
    (2000). Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. 275, 1226-1232. doi:10.1074/jbc.275.2.1226
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. George, M.,
    2. Ayuso, E.,
    3. Casellas, A.,
    4. Costa, C.,
    5. Devedjian, J. C. and
    6. Bosch, F.
    (2002). Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J. Clin. Invest. 109, 1153-1163. doi:10.1172/JCI0212969
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Gruessner, R. W. G. and
    2. Gruessner, A. C.
    (2013). The current state of pancreas transplantation. Nat. Rev. Endocrinol. 9, 555-562. doi:10.1038/nrendo.2013.138
    OpenUrlCrossRefPubMed
  23. ↵
    1. Heit, J. J.,
    2. Karnik, S. K. and
    3. Kim, S. K.
    (2006). Intrinsic regulators of pancreatic beta-cell proliferation. Annu. Rev. Cell Dev. Biol. 22, 311-338. doi:10.1146/annurev.cellbio.22.010305.104425
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Hess, D.,
    2. Li, L.,
    3. Martin, M.,
    4. Sakano, S.,
    5. Hill, D.,
    6. Strutt, B.,
    7. Thyssen, S.,
    8. Gray, D. A. and
    9. Bhatia, M.
    (2003). Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21, 763-770. doi:10.1038/nbt841
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Hu, J.,
    2. Yu, X.,
    3. Wang, Z.,
    4. Wang, F.,
    5. Wang, L.,
    6. Gao, H.,
    7. Chen, Y.,
    8. Zhao, W.,
    9. Jia, Z.,
    10. Yan, S. et al.
    (2013). Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr. J. 60, 347-357. doi:10.1507/endocrj.EJ12-0343
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ito, T.,
    2. Itakura, S.,
    3. Todorov, I.,
    4. Rawson, J.,
    5. Asari, S.,
    6. Shintaku, J.,
    7. Nair, I.,
    8. Ferreri, K.,
    9. Kandeel, F. and
    10. Mullen, Y.
    (2010). Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 89, 1438-1445. doi:10.1097/TP.0b013e3181db09c4
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kong, D.,
    2. Zhuang, X.,
    3. Wang, D.,
    4. Qu, H.,
    5. Jiang, Y.,
    6. Li, X.,
    7. Wu, W.,
    8. Xiao, J.,
    9. Liu, X.,
    10. Liu, J. et al.
    (2014). Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. Clin. Lab. 60, 1969-1976.
    OpenUrlPubMed
  28. ↵
    1. Kono, T. M.,
    2. Sims, E. K.,
    3. Moss, D. R.,
    4. Yamamoto, W.,
    5. Ahn, G.,
    6. Diamond, J.,
    7. Tong, X.,
    8. Day, K. H.,
    9. Territo, P. R.,
    10. Hanenberg, H. et al.
    (2014). Human adipose-derived stromal/stem cells protect against STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors. Stem Cells 32, 1831-1842. doi:10.1002/stem.1676
    OpenUrlCrossRefPubMed
  29. ↵
    1. Lechner, A.,
    2. Yang, Y.-G.,
    3. Blacken, R. A.,
    4. Wang, L.,
    5. Nolan, A. L. and
    6. Habener, J. F.
    (2004). No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes 53, 616-623. doi:10.2337/diabetes.53.3.616
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Lee, R. H.,
    2. Seo, M. J.,
    3. Reger, R. L.,
    4. Spees, J. L.,
    5. Pulin, A. A.,
    6. Olson, S. D. and
    7. Prockop, D. J.
    (2006). Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl. Acad. Sci. USA 103, 17438-17443. doi:10.1073/pnas.0608249103
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Leiter, E. H.
    (1982). Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc. Natl. Acad. Sci. USA 79, 630-634. doi:10.1073/pnas.79.2.630
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Lenzen, S.
    (2008). The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216-226. doi:10.1007/s00125-007-0886-7
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Livak, K. J. and
    2. Schmittgen, T. D.
    (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25, 402-408. doi:10.1006/meth.2001.1262
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Lopez, Y.,
    2. Lutjemeier, B.,
    3. Seshareddy, K.,
    4. Trevino, E. M.,
    5. Hageman, K. S.,
    6. Musch, T. I.,
    7. Borgarelli, M. and
    8. Weiss, M. L.
    (2013). Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. Curr. Stem Cell Res. Ther. 8, 46-59. doi:10.2174/1574888X11308010007
    OpenUrlCrossRefPubMed
  35. ↵
    1. McGuirk, J. P. and
    2. Weiss, M. L.
    (2011). Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review). Placenta 32 Suppl. 4, S304-S310. doi:10.1016/j.placenta.2011.04.013
    OpenUrlCrossRefPubMed
  36. ↵
    1. Nakamura, T.,
    2. Sakai, K.,
    3. Nakamura, T. and
    4. Matsumoto, K.
    (2011). Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol. 26 Suppl. 1, 188-202. doi:10.1111/j.1440-1746.2010.06549.x
    OpenUrlCrossRefPubMed
  37. ↵
    1. Nauta, A. J. and
    2. Fibbe, W. E.
    (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506. doi:10.1182/blood-2007-02-069716
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Paik, S. G.,
    2. Fleischer, N. and
    3. Shin, S. I.
    (1980). Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc. Natl. Acad. Sci. USA 77, 6129-6133. doi:10.1073/pnas.77.10.6129
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Peng, S.-W.,
    2. Zhu, L.-Y.,
    3. Chen, M.,
    4. Zhang, M.,
    5. Li, D.-Z.,
    6. Fu, Y.-C.,
    7. Chen, S.-R. and
    8. Wei, C.-J.
    (2009). Heterogeneity in mitotic activity and telomere length implies an important role of young islets in the maintenance of islet mass in the adult pancreas. Endocrinology 150, 3058-3066. doi:10.1210/en.2008-1731
    OpenUrlCrossRefPubMed
  40. ↵
    1. Ronnstrand, L.
    (2004). Signal transduction via the stem cell factor receptor/c-Kit. Cell. Mol. Life Sci. 61, 2535-2548. doi:10.1007/s00018-004-4189-6
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Rosengren, A. H.,
    2. Taneera, J.,
    3. Rymo, S. and
    4. Renstrom, E.
    (2009). Bone marrow transplantation stimulates pancreatic beta-cell replication after tissue damage. Islets 1, 10-18. doi:10.4161/isl.1.1.8529
    OpenUrlCrossRefPubMed
  42. ↵
    1. Shibuya, M.
    (2013). Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153, 13-19. doi:10.1093/jb/mvs136
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Taneera, J.,
    2. Rosengren, A.,
    3. Renstrom, E.,
    4. Nygren, J. M.,
    5. Serup, P.,
    6. Rorsman, P. and
    7. Jacobsen, S. E. W.
    (2006). Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate. Diabetes 55, 290-296. doi:10.2337/diabetes.55.02.06.db05-1212
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Tang, Q.,
    2. Chen, Q.,
    3. Lai, X.,
    4. Liu, S.,
    5. Chen, Y.,
    6. Zheng, Z.,
    7. Xie, Q.,
    8. Maldonado, M.,
    9. Cai, Z.,
    10. Qin, S. et al.
    (2013). Malignant transformation potentials of human umbilical cord mesenchymal stem cells both spontaneously and via 3-methycholanthrene induction. PLoS ONE 8, e81844. doi:10.1371/journal.pone.0081844
    OpenUrlCrossRefPubMed
  45. ↵
    1. Troyer, D. L. and
    2. Weiss, M. L.
    (2008). Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26, 591-599. doi:10.1634/stemcells.2007-0439
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Tuttle, R. L.,
    2. Gill, N. S.,
    3. Pugh, W.,
    4. Lee, J.-P.,
    5. Koeberlein, B.,
    6. Furth, E. E.,
    7. Polonsky, K. S.,
    8. Naji, A. and
    9. Birnbaum, M. J.
    (2001). Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat. Med. 7, 1133-1137. doi:10.1038/nm1001-1133
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Volarevic, V.,
    2. Arsenijevic, N.,
    3. Lukic, M. L. and
    4. Stojkovic, M.
    (2011). Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 29, 5-10. doi:10.1002/stem.556
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Wang, H.,
    2. Qiu, X.,
    3. Ni, P.,
    4. Qiu, X.,
    5. Lin, X.,
    6. Wu, W.,
    7. Xie, L.,
    8. Lin, L.,
    9. Min, J.,
    10. Lai, X. et al.
    (2014). Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats. Int. J. Mol. Med. 33, 263-270. doi:10.3892/ijmm.2013.1572
    OpenUrlCrossRefPubMed
  49. ↵
    1. Watson, N.,
    2. Divers, R.,
    3. Kedar, R.,
    4. Mehindru, A.,
    5. Mehindru, A.,
    6. Borlongan, M. C. and
    7. Borlongan, C. V.
    (2015). Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy 17, 18-24. doi:10.1016/j.jcyt.2014.08.009
    OpenUrlCrossRefPubMed
  50. ↵
    1. Weir, C.,
    2. Morel-Kopp, M.-C.,
    3. Gill, A.,
    4. Tinworth, K.,
    5. Ladd, L.,
    6. Hunyor, S. N. and
    7. Ward, C.
    (2008). Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ. 17, 395-403. doi:10.1016/j.hlc.2008.01.006
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Weiss, M. L.,
    2. Medicetty, S.,
    3. Bledsoe, A. R.,
    4. Rachakatla, R. S.,
    5. Choi, M.,
    6. Merchav, S.,
    7. Luo, Y.,
    8. Rao, M. S.,
    9. Velagaleti, G. and
    10. Troyer, D.
    (2006). Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24, 781-792. doi:10.1634/stemcells.2005-0330
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Weiss, M. L.,
    2. Anderson, C.,
    3. Medicetty, S.,
    4. Seshareddy, K. B.,
    5. Weiss, R. J.,
    6. VanderWerff, I.,
    7. Troyer, D. and
    8. McIntosh, K. R.
    (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 26, 2865-2874. doi:10.1634/stemcells.2007-1028
    OpenUrlCrossRefPubMed
View Abstract
Back to top

RSSRSS

Keywords

 Download PDF

Email
RESEARCH ARTICLE
Human umbilical cord matrix-derived stem cells exert trophic effects on β-cell survival in diabetic rats and isolated islets
Yunting Zhou, Qi Hu, Fuyi Chen, Juan Zhang, Jincheng Guo, Hongwu Wang, Jiang Gu, Lian Ma, Guyu Ho
Disease Models & Mechanisms 2015 8: 1625-1633; doi: 10.1242/dmm.021857
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Subject collections

Other journals from The Company of Biologists

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

Interviews – Sneh, Mami and Myumi

Photos of Sneh, Mami and Myumi

Continuing our ongoing support to early-career researchers, Sneh Harsh, Mami Uemura and Myumi Higashi share the story behind their latest DMM research, what this means for the field and where their science journey is heading to next.

Membrane trafficking in health and disease

Martin Lowe and his team summarise the major intracellular membrane trafficking pathways and associated molecular machineries, and describe how defects in these give rise to disease in humans, in an At a Glance article and poster.

Editor's choice - Familial hypercholesterolemia class II LDL receptor response to statin treatment

Nolan L Boyd and colleagues used an iPSC-based model of familiar hypercholeserolemia to investigate how mutant LDL receptors respond to statins.